Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.9550.

Several research analysts have recently issued reports on VYGR shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 15th. Finally, Wedbush dropped their price objective on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th.

Voyager Therapeutics Stock Down 7.1%

NASDAQ:VYGR opened at $4.95 on Monday. The company has a market capitalization of $274.58 million, a PE ratio of -2.68 and a beta of 0.95. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $8.27. The stock has a fifty day simple moving average of $4.17 and a 200-day simple moving average of $3.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The firm had revenue of $5.20 million for the quarter, compared to analyst estimates of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. As a group, equities analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of Voyager Therapeutics stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the completion of the sale, the chief financial officer owned 123,834 shares in the company, valued at approximately $591,926.52. This trade represents a 5.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.39% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its holdings in Voyager Therapeutics by 53.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company’s stock valued at $204,000 after buying an additional 21,149 shares during the period. Strs Ohio purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $256,000. Nuveen LLC purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $368,000. American Century Companies Inc. grew its holdings in Voyager Therapeutics by 7.2% in the 1st quarter. American Century Companies Inc. now owns 131,521 shares of the company’s stock valued at $445,000 after buying an additional 8,795 shares during the period. Finally, Hsbc Holdings PLC grew its holdings in Voyager Therapeutics by 74.0% in the 1st quarter. Hsbc Holdings PLC now owns 67,903 shares of the company’s stock valued at $229,000 after buying an additional 28,878 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.